BioMarin Pharmaceutical Inc. on Friday said the European Commission approved Voxzogo, a once-daily injection to treat achondroplasia, the most common form of disproportionate short stature in humans.
The San Rafael, Calif., biotechnology company said the approval covers the treatment of children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.
BioMarin said Voxzogo is the first medicine approved to treat children with achondroplasia in Europe. The U.S. Food and Drug Administration is currently reviewing BioMarin's application for Voxzogo, with a target action date of Nov. 20.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.